SCHEMBL23357933

SCHEMBL23357933

NC(=O)OC12CC(NC(=O)COc3ccc(Cl)cc3)(C1)C2

nearest known ligand 0.75

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 13/20 0.75
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20974142 0.86 ATF4 (1.00) ATF4NPC1RAB9ATSHRNPSR1
SCHEMBL30446215 0.84 ATF4 (0.79) ATF4NPC1RAB9ATSHRNPSR1
SCHEMBL19555369 0.84 ATF4 (0.83) ATF4NPC1RAB9ATSHRNPSR1
Hydrochloric Acid SCHEMBL20610394 0.83 ATF4 (0.81) ATF4NPC1RAB9ATSHRNPSR1
SCHEMBL21618354 0.82 ATF4 (0.79) ATF4NPC1RAB9ATSHRNPSR1
SCHEMBL21618322 0.81 ATF4 (0.83) ATF4NPC1RAB9ATSHRNPSR1
SCHEMBL23149137 0.81 ATF4 (0.89) ATF4NPC1RAB9ATSHRNPSR1
SCHEMBL20610381 0.81 ATF4 (0.89) ATF4NPC1RAB9ATSHRNPSR1
SCHEMBL19556192 0.81 ATF4 (0.89) ATF4NPC1RAB9ATSHRNPSR1
SCHEMBL23383768 0.81 ATF4 (0.78) ATF4NPC1RAB9ATSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES ATF4, EIF2B1, EIF4A1 ATF4 1/4885NPC1 909/4885RAB9A 3653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback